Concepedia

Publication | Open Access

Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial

DOIFull Paper Access

55

Citations

20

References

2021

Year

Riad Salem, Daneng Li, Nicolas Sommer, Sairy Hernandez, Wendy Verret, Beiying Ding, Riccardo Lencioni
Cancer Medicine

Abstract

These data highlight the improved ORR, DpR, and CR rates with ATEZO/BEV in unresectable HCC.

References

YearCitations

Page 1